-
The subscription of new shares has long been known, and there will be a new pharmaceutical stock next week!
Time of Update: 2022-08-15
Further improve the core competitiveness of enterprises Among them, the new drug research and development project in the fundraising project aims to invest in the research and development of a number of clinical and preclinical products, and provide patients with safe, effective and affordable high-quality drugs through innovative research and development to meet the urgent treatment needs.
-
Intensified competition in the industry, local pharmaceutical companies have begun to build production bases
Time of Update: 2022-08-15
billion target According to the plan, by 2030, Mindray Longhua Base will carry more than 60% of the production capacity of the group's supply chain, and cooperate with Mindray Medical Shenzhen Guangming Base to form a two-wheel drive pattern, leading the total output value of Mindray Medical Shenzhen's manufacturing sector to exceed 1,000 in 2030.
-
Overseas markets have become new drivers of growth, and pharmaceutical equipment companies have high enthusiasm for development
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] Recently, Chutian Technology, a leading domestic pharmaceutical equipment company, mentioned in an investigation that the company's headquarters plans to double the target of new orders for export business this year compared with 2021, and plans to achieve export business revenue around 2025 about 50% of total revenue .
-
On June 1, many pharmaceutical stocks such as Zejing Pharma hit their daily limit
Time of Update: 2022-08-15
13%; at the same time, the company is in the pre-expansion stage of drug listing and commercialization, and needs to invest a lot of pre-market expansion and academic promotion activities The 2021 annual report shows that Zejing Pharmaceutical will achieve revenue of 190 million yuan in 2021, a year-on-year increase of 588.
-
The medical sector was active, and many stocks such as Innovative Medical and Ogilvy Medical rose by the daily limit
Time of Update: 2022-08-15
The company started out in the hyaluronic acid business and occupies a dominant position in the domestic sodium hyaluronate medical beauty preparation field Amic is a leading non-surgical medical beauty company.
-
The research and development of new Chinese medicines has entered a period of rapid development, and these pain points need to be solved urgently
Time of Update: 2022-08-15
With the promotion of a series of policies to encourage and support the development of traditional Chinese medicine, such as the "Guiding Opinions on Inheriting and Innovative Development", the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for clinical trials of new Chinese medicines and new drug marketing authorization applications has also increased year by year .
-
Faced with intensified market competition, pharmaceutical equipment companies are further expanding their product lines
Time of Update: 2022-08-15
( A total of 49% of the shares held by minority shareholders of "Chutian Yunfei") Pharmaceutical equipment companies are further expanding their product lines (Source: Pharmaceutical Network) For example, recently, Truking Technology disclosed a plan for additional asset purchases, and plans to purchase its holding subsidiary, Truking Feiyun Pharmaceutical Equipment (Changsha) Co.
-
In the past week, many pharmaceutical companies have been rated as "buy" by institutions
Time of Update: 2022-08-15
14 yuan Capital Securities recently gave Kangchen Pharmaceutical a buy rating, and the current share price is 25.
-
In July, executives of pharmaceutical companies set off another wave of departures, and the industry environment is changing
Time of Update: 2022-08-15
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guocheng .
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guocheng .
-
The pharmaceutical industry has set off a wave of AI research and development, and it will also have great prospects in the pharmaceutical field
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to spee
-
Traditional Chinese medicine, CRO and other pharmaceutical sub-sectors pulled up, and Xintian Pharmaceuticals rose by the daily limit
Time of Update: 2022-08-15
Its business covers the whole chain of drug R&D and production, including drug discovery, pharmaceutical research, clinical trials, customized R&D and production, and registration application According to the data, Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as the core.
-
The development of traditional Chinese medicine continues to improve, and the pharmaceutical equipment of traditional Chinese medicine is constantly changing to "intelligent manufacturing"!
Time of Update: 2022-08-15
It will help more and more enterprises to achieve more efficient production With the development and application of new technologies such as the Internet of Everything, big data, and artificial intelligence, the positive shift to "intelligent manufacturing" brings more imagination to the traditional Chinese medicine industry.
-
Switzerland's revised organ transplant law allows those who do not refuse to be considered organ donors
Time of Update: 2022-08-15
(Headquarters reporter Yi Xin) On May 15, local time, Switzerland held a referendum on three proposals, namely, the revision of the "Organ Transplantation Law", the revision of the "Film Law" and the increase of funding for the European Border Agency, all of which were passed with a high approval rate .
-
The pharmaceutical companies that plan to win the seventh batch of Guocai have reported good news, and many stock prices have risen accordingly
Time of Update: 2022-08-15
44 yuan/box) The company announced that its two subsidiaries planned to win the bid for the seventh batch of national centralized drug procurement.
-
"14th Five-Year Plan" for Drug Regulatory Network Security and Informatization Construction
Time of Update: 2022-08-15
On May 11, the State Food and Drug Administration issued the "14th Five-Year Plan for Drug Regulatory Network Security and Informatization Construction" . The plan mentioned that the construction of
-
Under the pressure of centralized procurement and price reduction, how should generic drugs break through?
Time of Update: 2022-08-15
Behind this, it is actually driven by the centralized procurement policy, generic drug companies The cost for marketing has been gradually compressed, and the pricing power of drugs has shifted from the sales side to the production side For example, in the first batch of domestic procurement, Xinlitai, which lost its bid for its core product, clopidogrel hydrogen sulfate tablets, saw a sharp drop in the year-on-year growth rate of non-net profit in 2019 and 2020, respectively, by 54.
-
On August 8, 2 pharmaceutical stocks hit record highs in intraday trading
Time of Update: 2022-08-15
. On the news, Yaokang Biology recently replied to investors on the interactive platform that the company is currently focusing on the research and development, production, sales and related technical services of experimental animal mouse models, and for new businesses such as life science downstream and non-human primates.
-
Overview of China's hospital drug market in the first quarter of 2022
Time of Update: 2022-08-15
Figure 4 National-Hospital Drug Market-Scale and Growth Rate of 30 Provinces and Cities (MAT2022Q1) Overview of China's Hospital Drug Market In MAT2022Q1, the total sales of China's hospital drug market reached 976 Bn, a year-on-year increase of 2.
-
13 pharmaceutical companies sprint for IPO, but these companies have no products listed and no profits
Time of Update: 2022-08-15
It is reported that Suzhou Huyun plans to invest a total of 450 million yuan of raised funds this time, which will all be used for innovative drug R&D projects, innovative drug R&D and production base construction projects and supplementary working capital .
-
This cross-border photovoltaic pharmaceutical company has won the fourth consecutive board!
Time of Update: 2022-08-15
. In the "Letter of Concern", the Shenzhen Stock Exchange required Lvkang Biochemical to explain the reasons and necessity of the company's high premium acquisition under the condition that the underlying asset performance was in loss and the asset-liability ratio was high.
